In addition to his work as CMO of Himalaya, Dr. Li is Founder, DeltaMed, a leading Chinese niche CRO for pharmacovigilance, medical monitoring, medical writing, phase I study and regulatory & clinical development strategy.  From 2013 to 2018, Dr. Li was founder and CEO of Tigermed-IntelliPV and former CMO of Tigermed, where he established the pharmacovigilance, medical monitoring and medical information department.  He also led Tigermed’s medical and scientific affairs department.  From 1997-2013, he held several medical management roles in leading global pharma companies, including Quintiles, Abbott Laboratories, Sanofi Pasteur, BMS and Amylin.  He was involved 9 NDA submissions as global safety lead.  Dr. Li is a committee member of “Executive Management and Translational Medicine”, and an Industrial Distinguished Instructor of Tsinghua Medical School.  He instructs classes in “Clinical Trial Design” and “Good Practices for Clinical Trials”.  Dr. Li is also an Adjunct Professor and Counselor of “Clinical Research Center” at the medical school of Shanghai Jiaotong University. He is a professor and class chairman at YeeHong Business School. He is an advisor committee member of the Drug Information Association in China, an International Council for Harmonisation (ICH) expert in China, and China CDE advisor.  In addition, he is advisor or partner for several venture capitals. Dr. Li received his MD from Tongji Medical University, Peking Union Medical College.  He completed his postdoctoral fellowship in University of North Carolina studied under the Nobel Laureate, Professor Oliver Smithies.